Contineum Therapeutics Reports Positive PIPE-791 Data
SAN DIEGO, April 30, 2026 Contineum Therapeutics, Inc. announced positive topline results from its Phase 1b clinical trial of...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SAN DIEGO, April 30, 2026 Contineum Therapeutics, Inc. announced positive topline results from its Phase 1b clinical trial of...
INDIANAPOLIS, December 11, 2025 — Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 trial,...
